骨骼肌
生物
肌萎缩
刺激
下调和上调
肌钙蛋白
心肌细胞
肌球蛋白
肌节
肌钙蛋白I
肌原纤维
内分泌学
内科学
细胞生物学
医学
生物化学
基因
心肌梗塞
作者
Shelby Giza,Jorge Mojica-Santiago,Maddalena Parafati,Legrand K. Malany,Don Platt,Christine E. Schmidt,Paul M. Coen,Siobhan Malany
出处
期刊:Aging Cell
[Wiley]
日期:2022-06-02
卷期号:21 (7)
被引量:20
摘要
Abstract Microphysiological systems (MPS), also referred to as tissue chips, incorporating 3D skeletal myobundles are a novel approach for physiological and pharmacological studies to uncover new medical treatments for sarcopenia. We characterize a MPS in which engineered skeletal muscle myobundles derived from donor‐specific satellite cells that model aged phenotypes are encapsulated in a perfused tissue chip platform containing platinum electrodes. Our myobundles were derived from CD56 + myogenic cells obtained via percutaneous biopsy of the vastus lateralis from adults phenotyped by age and physical activity. Following 17 days differentiation including 5 days of a 3 V, 2 Hz electrical stimulation regime, the myobundles exhibited fused myotube alignment and upregulation of myogenic, myofiber assembly, signaling and contractile genes as demonstrated by gene array profiling and localization of key components of the sarcomere. Our results demonstrate that myobundles derived from the young, active (YA) group showed high intensity immunofluorescent staining of α‐actinin proteins and responded to electrical stimuli with a ~1 μm displacement magnitude compared with non‐stimulated myobundles. Myobundles derived from older sedentary group (OS) did not display a synchronous contraction response. Hypertrophic potential is increased in YA‐derived myobundles in response to stimulation as shown by upregulation of insulin growth factor (IGF‐1), α‐actinin (ACTN3, ACTA1) and fast twitch troponin protein (TNNI2) compared with OS‐derived myobundles. Our MPS mimics disease states of muscle decline and thus provides an aged system and experimental platform to investigate electrical stimulation mimicking exercise regimes and may be adapted to long duration studies of compound efficacy and toxicity for therapeutic evaluation against sarcopenia.
科研通智能强力驱动
Strongly Powered by AbleSci AI